“Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin”
Michel Bolla, M.D., Dionisio Gonzalez, M.D., Padraig Warde, M.D., Jean Bernard Dubois, M.D., René-Olivier Mirimanoff, M.D., Guy Storme, M.D., Jacques Bernier, M.D., Abraham Kuten, M.D., Cora Sternberg, M.D., Thierry Gil, M.D., Laurence Collette, M.Sc., and Marianne Pierart
In this study 415 patients with
locally advanced prostate
cancer were randomly assigned to receive radiotherapy
alone or radiotherapy plus treatment with goserelin
from 1987 to 1995. Goserelin is an agonist analogue
of gonodotropin-releasing hormone that reduces testosterone
secretion. Patients were approximately 71 years old.
Those who were treated with radiation and goserelin
also received cyproterone acetate during the first month
to restrict the rise in testosterone
associated with goserelin. Only 401 of the 415 patients
were available and tracked for 45 months. After 5 years
79% of patients in the combined-treatment group achieved
overall survival, compared to 62% in the radiotherapy
group. In the combined-treatment group 85% were free
of disease and in the radiotherapy group 48% were free
“10-Year Outcome for Men With Localized Prostate Cancer Treated With External Beam Radiation Therapy:: Results of a Cohort Study”
ZIETMAN, A. L. *; CHUNG, C. S.; COEN, J. J.; SHIPLEY, W. U. Journal of Urology. 171(1):210-214, January 2004.
The goal of this study was to determine
how beneficial conventional dose external beam radiation
therapy would be to patients with localized prostate
cancer. From 1991 to 1993, 205 patients with stage
T1 or stage
T2 cancer received radiation therapy.
Follow-up was done for 114 months with patients without
disease. Generally patients were around 72 years at
treatment. After 5 years 78% of patients achieved overall
survival, and in 10 years the overall survival was 53%.
After 10 years 18% had a risk of local failure and metastatic
disease, 49% had a risk of being free of biochemical
failure, and 127 out of the 205 treated patients (62%)
were still alive.
“Biochemical Disease-Free Survival in Men Younger Than 60 Years With Prostate Cancer Treated With External Beam Radiation”
ROSSER, CHARLES J.; CHICHAKLI, RAMSAY; LEVY, LAWRENCE B.; KUBAN, DEBORAH A.; SMITH, LEWIS G.; PISTERS, LOUIS L. Journal of Urology. 168(2):536-541, August 2002.
In this study doctors hoped to determine
the rate of biochemical failure in patients younger
than 60 and older than 60 at the time of treatment with
external beam radiation for localized or locally advanced
prostate cancer. Doctors reviewed 964 medical records
of patients who received full dose radiotherapy. Doctors
than analyzed patient’s PSA
levels 3 to 6 months after treatment
and routinely every 3 to 6 months thereafter for approximately
48 months. There were 98 patients in the group 60 years
or younger and 866 older than 60. Biochemical failure
was found in 46 (47%) of the younger group and 261(30%)
of the older group. Biochemical disease-free survival
rates at 5 and 7 years were 55% and 47% in the younger
group and 65% and 59% in the older group.